金斯瑞(01548.HK)引入高瓴为主要股东 股价升幅续扩至22%创逾两年高交投活跃
金斯瑞生物科技(01548.HK)引入高瓴为主要股东,午後复牌股价高开1.8%破顶後,升幅持续扩大,最高见24.2元,创逾两年高,现造24元,急涨22%,成交急增至4,194万股,涉资9.3亿元。
金斯瑞公布,控股股东GS Corp告知,已於昨天订立协议,以每股18.658元(较停牌前折让约5%),向买方GNS Holding出售6,178.91万股持股或占已扩大後股本约3%。同时,公司根据一般授权也向GNS发行约5%股份,完成後,GNS将成为公司主要股东持股约8%。高瓴资本为GNS唯一投资管理人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.